Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Massachusetts Healthcare Journal.
Press releases published on August 18, 2025
ONWARD Medical Receives FDA IDE Approval to Initiate the Empower BP Pivotal Study with the ARC-IM System
THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE 7(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014) The investigational device exemption (IDE) allows initiation of a global pivotal study designed to assess the safety and …
ACMA Announces Newly Elected National Board Members
Little Rock, AR, Aug. 18, 2025 (GLOBE NEWSWIRE) -- The American Case Management Association (ACMA) is pleased to announce the results of the 2025 National Board of Directors elections. The following distinguished professionals have been elected to serve on …
Whitsons and The Abbey Group Bring Local Flavor to New England Schools
Pittsfield, VT, Aug. 18, 2025 (GLOBE NEWSWIRE) -- From Vermont’s rolling dairy farms to Massachusetts’ coastal produce markets, a new partnership is reshaping how students across New England experience school meals. Whitsons Culinary Group® and The Abbey …
Affidea partners with Skin Analytics to improve access to skin cancer assessment across Europe using AI technology
THE HAGUE, The Netherlands, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Affidea, a leading pan-European provider of community-based polyclinics, advanced diagnostics, and multi-specialist care, including oncology, has entered a strategic partnership with Skin …
Global Ophthalmology Drugs Market to Reach USD 26.28 Billion by 2030 | MarketsandMarkets™
Delray Beach, FL, Aug. 18, 2025 (GLOBE NEWSWIRE) -- North America leads market expansion as companies advance next-generation ophthalmic therapies to address rising prevalence of vision-threatening diseases The global ophthalmology drugs market, valued at …
Hapbee Secures Strategic Backing and Commercial Agreement to Enter Multi-Billion Dollar Asian Wellness Market
VANCOUVER, British Columbia, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Hapbee Technologies Inc. (“Hapbee” or the “Company”) (TSXV: HAPB | OTCQB: HAPBF | FWB: HA1) today announced that Smile Group, a prominent Asia‑based venture builder and growth partner, has made …
First Patient Enrolled in Merit Medical’s WRAPSODY (WRAP) North America Registry
The WRAP North America registry is a prospective, multicenter study designed to collect real-world safety and effectiveness data on the WRAPSODY® Cell-Impermeable Endoprosthesis (CIE). The first WRAP North America patient was enrolled at Bluff City …
European Commission Grants Approval of OGSIVEO® (nirogacestat) for the Treatment of Adults with Desmoid Tumors
STAMFORD, Conn., Aug. 18, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc., a healthcare company of Merck, announced today that the European Commission (EC) granted marketing authorization for OGSIVEO® (nirogacestat), an oral gamma secretase …
Autonomix Medical, Inc. to Participate in Virtual Investor Webinar Hosted by Ladenburg Thalmann & Co. Inc.
Live video webcast on Thursday, August 21st at 1:00 PM ET Register here THE WOODLANDS, TX, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing precision …
European Commission Grants Approval of OGSIVEO® (nirogacestat) for the Treatment of Adults with Desmoid Tumors
STAMFORD, Conn., Aug. 18, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany, announced today that the European Commission (EC) granted marketing authorization for OGSIVEO® (nirogacestat), an …
Press Release Biocartis NV: Biocartis Welcomes Mike Kreitzinger as Senior Vice President of Global Business Development
PRESS RELEASE - 08/18/2025, 09:00 AM EDT Biocartis Welcomes Mike Kreitzinger as Senior Vice President of Global Business Development Itasca (IL), United States, August 18th, 2025 – Biocartis Group of Companies (“Biocartis”), an innovative molecular …
Capricor Therapeutics Announces First Subjects Dosed in Phase 1 Clinical Trial of Novel Exosome-Based Vaccine
First-in-human trial of Capricor’s StealthX™ vaccine initiated under HHS’s Project NextGen Trial conducted and funded by the National Institute of Allergy and Infectious Diseases (NIAID) SAN DIEGO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics ( …
Journey Medical Corporation to Present at the Emerging Growth Conference
SCOTTSDALE, Ariz., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical,” “the Company,” “we” or “our”), a commercial-stage pharmaceutical company primarily focused on selling and marketing FDA-approved …
Biodexa Announces Enrolment of First Patients into Pivotal Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)
August 18, 2025 Biodexa Announces Enrolment of First Patients into Pivotal Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP) Opportunity to be First Mover in $7.3Bn Addressable Market Biodexa Pharmaceuticals PLC (“Biodexa” or “the Company”), ( …
Quoin Pharmaceuticals Appoints New Chief Financial Officer to Support Commercialization Strategy
ASHBURN, Va., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late clinical stage specialty pharmaceutical company focused on rare and orphan diseases, today announced the appointment of its new …
NeuroOne® Receives FDA 510(k) Clearance for OneRF® Trigeminal Nerve Ablation System to Treat Facial Pain
FDA Clearance Further Validates Technology Platform and Offers Alternatives to Pharmaceutical and Invasive Surgical Treatments EDEN PRAIRIE, Minn., Aug. 18, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or …
Impact Biomedical Inc (IBO) Announces 3F™ US Patent Issue
HOUSTON, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Impact Biomedical Inc. (IBO) is pleased to announce that the US Patent and Trademark Office has issued U.S. patent No. 12,357,584 B2 entitled “Composition and Method of Controlling Infectious Diseases with …
Boehringer Ingelheim and Palatin Technologies to develop potential first-in-class melanocortin receptor targeted treatment for patients with retinal diseases
· Collaboration strengthens Boehringer’s pipeline in Eye Health. · Many patients with diabetic retinopathy (DR) continue to experience vision loss or treatment fatigue, underscoring an unmet need. · Melanocortin receptor agonists offer …